Neurizon Therapeutics Limited (ASX:NUZ)
Australia · Delayed Price · Currency is AUD 0.0780
0.00 (0.00%)
Sep 11, 2026, 11:11 AM AEST
Neurizon Therapeutics Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 12.69 | 4.16 | 9.71 | 2.71 | 2.42 |
Short-Term Investments | 0.02 | 0.02 | 1.02 | 0.02 | 0 |
Cash & Short-Term Investments | 12.71 | 4.18 | 10.73 | 2.72 | 2.42 |
Cash Growth | 204.04% | -61.03% | 294.23% | 12.47% | -19.99% |
Accounts Receivable | - | - | 0.02 | 0.15 | 0.19 |
Other Receivables | 10.41 | - | - | - | - |
Receivables | 10.41 | - | 0.02 | 0.15 | 0.19 |
Inventory | - | - | - | - | 1.04 |
Prepaid Expenses | 0.4 | 0.1 | 0.25 | 0.09 | 0.06 |
Other Current Assets | 0.16 | 0.08 | 0.13 | 0.07 | 0.02 |
Total Current Assets | 23.69 | 4.36 | 11.12 | 3.02 | 3.73 |
Property, Plant & Equipment | 0.01 | 0 | - | 0 | 3.24 |
Other Intangible Assets | - | - | - | 3.11 | 3.11 |
Total Assets | 23.7 | 4.36 | 11.12 | 6.13 | 10.08 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 3.79 | 1.27 | - | 0.93 | 0.6 |
Accrued Expenses | 0.27 | 0.21 | 0.14 | 0.26 | 0.21 |
Short-Term Debt | - | - | - | - | 0.21 |
Current Portion of Long-Term Debt | 3.31 | - | - | - | - |
Current Portion of Leases | - | - | - | 0.16 | 0.14 |
Other Current Liabilities | 3.59 | 0.05 | 0.76 | - | - |
Total Current Liabilities | 10.95 | 1.53 | 0.9 | 1.35 | 1.17 |
Long-Term Leases | - | - | - | 0.89 | 1.04 |
Pension & Post-Retirement Benefits | 0.02 | 0 | 0 | 0 | 0.03 |
Total Liabilities | 10.97 | 1.54 | 0.9 | 2.24 | 2.23 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 98.97 | 78.8 | 69.94 | 57.63 | 55.34 |
Retained Earnings | -86.96 | -77.98 | -64.13 | -56.46 | -50.25 |
Comprehensive Income & Other | 0.72 | 2 | 4.42 | 2.72 | 2.75 |
Shareholders' Equity | 12.73 | 2.82 | 10.23 | 3.89 | 7.84 |
Total Liabilities & Equity | 23.7 | 4.36 | 11.12 | 6.13 | 10.08 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 3.31 | - | - | 1.05 | 1.39 |
Net Cash (Debt) | 9.4 | 4.18 | 10.73 | 1.67 | 1.03 |
Net Cash Growth | 124.85% | -61.03% | 541.45% | 61.66% | -40.75% |
Net Cash Per Share | 0.02 | 0.01 | 0.03 | 0.01 | 0.00 |
Filing Date Shares Outstanding | 775.1 | 492.31 | 486.22 | 348.77 | 316.91 |
Total Common Shares Outstanding | 763.64 | 492.31 | 445.02 | 347.47 | 316.91 |
Working Capital | 12.74 | 2.82 | 10.23 | 1.67 | 2.56 |
Book Value Per Share | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 |
Tangible Book Value | 12.73 | 2.82 | 10.23 | 0.78 | 4.73 |
Tangible Book Value Per Share | 0.02 | 0.01 | 0.02 | 0.00 | 0.01 |
Machinery | - | - | - | - | 3.63 |